Kuang Ye-Hong, Zhu Wu, Lin Ge, Cheng La-Mei, Qin Qun, Huang Zhi-Jun, Shi Yu-Ling, Zhang Chun-Lei, Xu Jin-Hua, Yan Ke-Xiang, Lv Cheng-Zhi, Li Wei, Han Qin, Stambler Ilia, Lim Lee Wei, Chakrabarti Sasanka, Ulfhake Brun, Min Kyung-Jin, Ellison-Hughes Georgina, Cho William C, Jin Kunlin, Yao Danni, Lu Chuanjian, Zhao Robert Chunhua, Chen Xiang
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
China Dermatologist Association, China.
Aging Dis. 2024 Jun 4;16(3):1363-1377. doi: 10.14336/AD.2024.0012.
Psoriasis is an immune-mediated, chronic, relapsing, inflammatory, systemic disease induced by individual-environmental interactions, and is often lifelong because of the difficulty of treatment. In recent years, a variety of targeted therapies, including biologics, have improved the lesions and quality of life of most psoriasis patients, but they still do not address the problem of relapse and may be associated with decreased efficacy or adverse events such as infections over time. Therefore, there is an urgent need for breakthroughs in psoriasis treatment and in relapse-delaying and non-pharmacologic strategies, and stem cell therapy for psoriasis has emerged. In recent years, research on stem cell therapy for psoriasis has received a lot of attention, however, there is no reference standard as well as consensus in this field of research. Therefore, according to the latest consensus and guidelines, combined with relevant literature reports, clinical practice experience and the results of discussions with experts, this consensus specifies the types of stem cells commonly used in the treatment of psoriasis, the methods, dosages, and routes of stem cell therapy for psoriasis, as well as the clinical evaluations (efficacy and safety) of stem cell therapy for psoriasis. In addition, this consensus also provides normative standards for the processes of collection, preparation, preservation and quality control of stem cells and their related products, as well as recommendations for the management of stem cells during infusion for the treatment of psoriasis. This consensus provides the latest specific reference standards and practice guidelines for the field of stem cell therapy for psoriasis.
银屑病是一种由个体与环境相互作用引发的免疫介导的慢性、复发性、炎症性全身性疾病，由于治疗困难，通常会伴随终生。近年来，包括生物制剂在内的多种靶向治疗方法改善了大多数银屑病患者的皮损状况和生活质量，但仍未解决复发问题，且随着时间推移可能出现疗效降低或感染等不良事件。因此，银屑病治疗以及延缓复发和非药物治疗策略亟待取得突破，银屑病的干细胞治疗应运而生。近年来，银屑病干细胞治疗的研究受到广泛关注，然而，该研究领域尚无参考标准和共识。因此，根据最新的共识和指南，结合相关文献报道、临床实践经验以及与专家讨论的结果，本共识明确了银屑病治疗中常用的干细胞类型、银屑病干细胞治疗的方法、剂量、途径，以及银屑病干细胞治疗的临床评估（疗效和安全性）。此外，本共识还为干细胞及其相关产品的采集、制备、保存和质量控制过程提供了规范标准，以及银屑病治疗输液过程中干细胞管理的建议。本共识为银屑病干细胞治疗领域提供了最新的具体参考标准和实践指南。
